Calyxo

Calyxo is a commercial-stage medical device company targeting the significant clinical and economic burden of kidney stone disease. Its flagship product, the CVAC System, integrates laser lithotripsy, irrigation, dynamic aspiration, and stone collection into a single platform to perform the proprietary SURE (Steerable Ureteroscopic Renal Evacuation) Procedure. The company, led by a seasoned team with prior successful exits in urology, is positioned to capture market share in the global kidney stone management sector by addressing the unmet need for reliable, single-procedure stone clearance. Calyxo is currently in the commercial launch phase, supported by clinical evidence from a randomized controlled trial.

The CVAC System is an integrated, single-platform medical device that combines laser lithotripsy, microjet irrigation, dynamic vacuum aspiration, and stone collection to perform the SURE Procedure for complete kidney stone clearance.

Calyxo competes in the kidney stone management device market against major players like Boston Scientific, Olympus, and Stryker, who offer lasers, ureteroscopes, and passive retrieval devices. Its primary competitive advantage is the integrated, active aspiration of the CVAC System, which directly addresses the clinical limitation of fragment retention associated with standard ureteroscopy. It competes on clinical outcome (clearance rate) rather than just device functionality.